Biomedical subjects

C Lévy-Piedbois

Publications and source records attributed to C Lévy-Piedbois.

3 recordsLinked to original sources

PubMed2001

[Conformational radiotherapy: economic evaluation].

Conformational radiotherapy is more and more used. It seems that this kind of treatment requests more manpower and material than 2D techniques. The purpose was to estimate its cost. We first tried to estimate the development of 3D radiotherapy. Then we calculated its relative cost compared to classical radiation therapy. To estimate relative costs, we first used the official catalogue. Then we reported results of a study performed in 1998 in two different radiotherapy departments. We conclude that 3D treatment are more expensive. The incremental cost is mainly related to that of dosimetry.

Diagnostic Imaging↗

PubMed1997

[Late effects of radiotherapy in children].

Although most pediatric tumors can be cured with lower doses of radiation than their adult counterparts, long-term radiation-induced complications and sequelae remain a major concern both in terms of frequency and intensity. Most of them have been extensively documented in the pre-chemotherapeutic era like those affecting bone, cartilage and soft tissue growth or CNS and endocrine glands. More recently the emphasis has been put on the apparent increasing incidence of reported second malignancies. This could have been favored by the chemo-radiation combinations used in most children but also has been made possible mainly by the extensive follow-up of the increasing cohort of cured children.

Adolescent↗

PubMedDate not supplied

[Radiotherapy for leukemias and lymphomas in children].

Children treated for malignant hemopathy have a very good prognosis, yet late effects of the treatments on the length, endocrine function, cognitive function and the risk of secondary malignant tumors must be decreased. These toxicities are described in this article. New protocols and radiation techniques have been developed to reduce these effects. Radiotherapy is prescribed in the treatment of non-Hodgkin lymphoma to prevent high risk of meninges recurrences or to treat meninges disease associated with chemotherapy. Doses of cranial irradiation are limited to 24 Gy. A SFOP trial concluded that doses of 20 Gy are sufficient after good responses to chemotherapy for the treatment of Hodgkin's disease. The target volume is reduced to the initial site of the disease.

Brain Neoplasms↗